Research Interests
Biologic agents in the treatment of rheumatic diseases.
Research Summary
Research Highlights
Personal
Education
UBC, B.Sc., Pharmacy,
UBC, MD,
Affiliations
Recent Publications
•Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis Rheum 54(8):2550-7, (Aug) 2006.
•”Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, Senecal JL, Zummer M, Edworthy S, Sibley J, Pope J, Ensworth S, Ramsey-Goldman R, Hanly
•JG. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 15(12):835-9, 2006.”
•Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, LJP-394-90-90 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 58(8):2470-80, (Aug) 2008.
•Ensworth S. Pregnancy and Biologic Disease Modifying Anti-Rheumatic Drugs. J Canadian Rheumatology Assoc 18(1): 30-21, (Spring) 2008.
•Goligher EC, Pouchot J, Brant R, Kherani RB, Avina-Zubieta JA, Lacaille D, Lehman AJ, Ensworth S, Kopec J, Esdaile JM, Liang MH. Minimal clinically important difference for seven measures of fatigue in patients with Systemic Lupus Erythematosus. J Rheumatol 35(4):635-42, (March) 2008.
•Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S, Kopec J, Esdaile JM, Liang MH. Determination of the minimal clinically important difference for seven fatigue measures in Rheumatoid Arthritis. J Clin Epidemiol 61(7):705-13,(March) 2008.